NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

A Postmarketing Study of LEQEMBI in South Korean Participants With Alzheimer's Disease

RecruitingN/A

Sponsor: Eisai Korea Inc.

Conditions: Alzheimer's Disease

Interventions: No Intervention

Countries: United States

The primary purpose of this study is to evaluate safety of LEQEMBI in the real-world clinical setting as reported by events of amyloid-related imaging abnormalities (ARIA)-edema (ARIA-E), ARIA-hemosiderin deposition (ARIA-H), symptomatic ARIA-E, symptomatic ARIA-H, and intracerebral hemorrhage (ICH) greater-than 1 centimeter (cm) in patients treated with LEQEMBI.

Eligibility overview

Sex: ALL

Age: 19 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Enrolled in JOY-ALZ before the decision to treat with LEQEMBI
* The clinical decision to treat with LEQEMBI has already been made
* Provides written informed consent for the use of medical information to be shared with Eisai Korea Inc.

Exclusion Criteria:

* Currently participating in an interventional clinical study

Locations (1)

Nutley, New Jersey, United States